---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-23-005946"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T16:26:07.626407+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Alzamend Neuro updates investor presentation for April 2023; no material new disclosures

## Summary
- Company furnished an updated corporate presentation (Exhibit 99.1) used for investor meetings.
- Presentation provides overview of therapeutic drugs for Alzheimer's and other neurodegenerative diseases.
- Information furnished under Regulation FD; not deemed filed for SEC or incorporated by reference.
- No specific pipeline updates, financial data, or clinical milestones disclosed with this filing.

## SEC filing metadata
- accession: 0001214659-23-005946
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465923005946/0001214659-23-005946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465923005946/r4252308k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-23-005946
- JSON: https://secwatch.observer/filing/0001214659-23-005946.json
- Plain text: https://secwatch.observer/filing/0001214659-23-005946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.